Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $25
Mizuho analyst Salim Syed maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $30 to $25.
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways:
Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule
The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Outlook For Coherus BioSciences
Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Coherus BioSciences will report an earnings per share (EPS) of $-0.48.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.
